Why Adial Pharmaceuticals Inc (ADIL) Stock Is Rising
As of 2026-08-07, Adial Pharmaceuticals Inc (ADIL) has a next-year EPS growth estimate of 60.71%. Featured in our EPS revision report on 2026-08-07.
Why ADIL Stock Is Rising
- +EPS Estimate Upgraded: Analysts raised Adial Pharmaceuticals Inc's next-year EPS growth estimate from 60.23% to 60.71% on 2026-08-03.
- ·Current-Year Growth: Projected at 73.62%, supporting the forward estimate revision.
News Context
The primary driver is the EPS estimate upgrade for next-year growth from 60.23% to 60.71% on 2026-08-03. That revision plausibly connects to Adial’s announced acquisition of Azora Therapeutics and up to $64 million financing, which expands its pipeline and funding. The stock’s continued rally suggests momentum beyond the initial revision, reinforced by headlines citing a major pipeline overhaul.
Generated 2026-08-07 · news as of 2026-08-07
Current Snapshot
- Sector
- Healthcare
- Industry
- Biotechnology
- EPS growth next year
- 60.71%
- EPS growth this year
- 73.62%
- EPS next quarter (est)
- -$1.03
- Last price
- $4.80
EPS Revision History
| Date | EPS Next Y | EPS This Y | Next Q (est) | Price |
|---|---|---|---|---|
| 2026-08-07 | 60.71% | 73.62% | -$1.03 | $4.80 |
| 2026-08-06 | 60.71% | 73.62% | -$1.03 | $4.80 |
| 2026-08-05 | 60.71% | 73.62% | -$1.03 | $4.05 |
| 2026-08-04 | 60.71% | 73.62% | -$1.03 | $3.80 |
| 2026-08-03 | 60.71% | 73.62% | -$1.03 | $3.64 |
| 2026-08-02 | 60.23% | 67.76% | -$1.02 | $3.34 |
| 2026-07-31 | 60.23% | 67.76% | -$1.02 | $3.34 |
| 2026-07-30 | 60.23% | 67.76% | -$1.02 | $3.29 |
| 2026-07-29 | 60.23% | 67.76% | -$1.02 | $3.15 |
| 2026-07-28 | 60.23% | 67.76% | -$1.02 | $2.95 |
| 2026-07-27 | 60.23% | 67.76% | -$1.02 | $2.81 |
| 2026-07-26 | 60.23% | 67.76% | -$1.02 | $2.78 |
| 2026-07-24 | 60.23% | 67.76% | -$1.02 | $2.78 |
| 2026-07-23 | 60.23% | 67.76% | -$1.02 | $2.68 |
| 2026-07-22 | 60.23% | 67.76% | -$1.02 | $2.70 |
| 2026-07-21 | 60.23% | 67.76% | -$1.02 | $2.74 |
| 2026-07-20 | 60.23% | 67.76% | -$1.02 | $2.73 |
| 2026-07-19 | 60.23% | 67.76% | -$1.02 | $2.80 |
| 2026-07-17 | 60.23% | 67.76% | -$1.02 | $2.80 |
| 2026-07-16 | 60.23% | 67.76% | -$1.02 | $2.79 |
| 2026-07-15 | 60.23% | 67.76% | -$1.02 | $2.72 |
| 2026-07-14 | 60.23% | 67.76% | -$1.02 | $2.65 |
| 2026-07-13 | 60.23% | 67.76% | -$1.02 | $2.83 |
| 2026-07-12 | 60.23% | 67.76% | -$1.02 | $2.78 |
| 2026-07-09 | 60.23% | 67.76% | -$1.02 | $2.80 |
| 2026-07-08 | 60.23% | 67.76% | -$1.02 | $2.87 |
| 2026-07-07 | 60.23% | 67.76% | -$1.02 | $2.91 |
| 2026-07-06 | 60.23% | 67.76% | -$1.02 | $2.90 |
| 2026-07-05 | 60.23% | 67.76% | -$1.02 | $2.90 |
| 2026-07-02 | 60.23% | 67.76% | -$1.02 | $2.90 |
Reports Featuring ADIL
Recent News
- Adial Pharmaceuticals Expands Executive Leadership Team and Closes PIPE FinancingGlobeNewswire
- ADIL Stock Eyes Best Day In Over 5 Years Major Pipeline Overhaul And $64M Raise Fuel RallyStocktwits
- Adial Pharmaceuticals Announces Acquisition of Azora Therapeutics and up to $64 Million FinancingGlobeNewswire
Screen Performance
Aggregate stats across all 1928 tickers our top-EPS-revision screen has flagged over the past 128 days.
- Median return since detection
- +3.1%
- % of tickers in the green
- 56%
- Median return on winners
- +20.6%
- Large revisions captured
- 1312
Past detection performance reflects the price change between when a ticker first entered our screen and the most recent observation. Not a forward-looking forecast.
Also Tracked by Our Screen
Frequently Asked Questions
Why did Adial Pharmaceuticals Inc (ADIL) stock go up recently?▾
Adial Pharmaceuticals Inc (ADIL) stock has risen following an analyst upgrade of its next-year EPS growth estimate from 60.23% to 60.71% on 2026-08-03. EPS estimate upgrades are among the strongest leading indicators of stock outperformance.
What is Adial Pharmaceuticals Inc's next-year EPS growth estimate?▾
As of 2026-08-07, Adial Pharmaceuticals Inc (ADIL) has a next-year EPS growth estimate of 60.71%, based on analyst consensus.
When was the latest EPS estimate revision for ADIL?▾
The most recent revision occurred on 2026-08-03, when analysts adjusted the next-year EPS growth estimate from 60.23% to 60.71%.
What sector and industry does Adial Pharmaceuticals Inc belong to?▾
Adial Pharmaceuticals Inc operates in the Healthcare sector, specifically the Biotechnology industry.
How often is this EPS estimate data updated?▾
EPS revision data is refreshed daily from analyst consensus estimates. ADIL appears on this page because it was flagged by our daily top-EPS-revision-performer screen.
EPS revision data sourced from analyst consensus estimates, refreshed daily. Adial Pharmaceuticals Inc (ADIL) appears here because it was detected by our daily top-EPS-revision-performer screen.